Protein |
Other Names |
Species |
Catalog Number |
CTRP1 |
C1qTNF1 |
H |
9268-TN |
CTRP1 |
C1qTNF1 |
M |
Coming soon |
CTRP2 |
C1qTNF2 |
H |
9436-TN
(Coming Soon) |
CTRP3 |
C1qTNF3, CORS26,
Cartducin, Cartonectin |
H |
9398-TN
(Coming Soon) |
CTRP4 |
C1qTNF4, ZACRP4 |
H |
8357-TN |
CTRP4 |
C1qTNF4, ZACRP4 |
M |
Coming soon |
CTRP5 |
C1qTNF5 |
H, M |
Coming soon |
CTRP9 |
C1qTNF9, AQL1 |
H |
6537-TN |
CTRP10 |
C1qTNF10, C1qL2 |
H |
9189-TN |
CTRP11 |
C1qTNF11, C1qL4 |
H |
Coming soon |
CTRP13 |
C1qTNF13, C1qL3 |
H |
9115-TN |
CTRP14 |
C1qTNF14, C1qL1 |
H |
9134-TN |
CTRP (C1q/TNF-related proteins) proteins constitute a conserved, structurally related family of 15 members. Every CTRP protein contains a signal peptide, an N-terminal domain with one or more conserved Cysteines, a collagen-like domain, and a C-terminal globular C1q domain. All are trimeric, and can also form high order oligomers. CTRP proteins are secreted and detected in the circulation. Receptors include members of the brain-specific angiogenesis inhibitor (BAI) subfamily of adhesion G-protein-coupled receptors.
These relatively unknown proteins show great potential for new scientific discovery with studies indicating involvement with cardiovascular disorders, insulin-sensitization, inflammation, and angiogenesis.
We offer a growing selection of bioactive CTRP family proteins that are exclusive to R&D Systems.
Figure 1. Both CTRP1/C1qTNF1 and CTRP2/C1qTNF2 Induce Phosphorylation of AMPK and ACC. Treatment of C2C12 differentiated myocytes with 10 µg/ml of Recombinant Human CTRP2/C1qTNF2 (lane 1) (Catalog # 9436-TN; Coming soon) or 10 µg/ml of Recombinant Human CTRP1/C1qTNF1 (lane 2) (Catalog # 9268-TN) for 1 hour results in phosphorylation of AMPK and ACC above levels detected in untreated C2C12 differentiated myocytes (lane 3).
Figure 2. Recombinant Human CTRP3/C1qTNF3/CORS26 Induces Proliferation in C2C12 myoblasts. Treatment of undifferentiated C2C12 myoblasts with a dose range of Recombinant Human CTRP3/C1qTNF3/CORS26 (Catalog # 9398-TN; Coming soon) results in increased proliferation with an ED50 = 1-6 µg/ml.
Figure 3. Recombinant Human CTRP1/C1qTNF1 Binds to Recombinant Human BAI3 in an ELISA Binding Assay. When Recombinant Human BAI3 (Catalog # 9106-BA) is coated on an ELISA plate, Recombinant Human CTRP1/C1qTNF1 (Catalog # 9268-TN) binds with an ED50 = 500 ng/ml.
Figure 4. Recombinant Human C1qTNF10/C1qL2 Binds to Recombinant Human BAI2 in an ELISA Binding Assay. When Recombinant Human C1qTNF10/C1qL2 (Catalog # 9189-TN) is coated on an ELISA plate, Recombinant Human BAI2 (Catalog # 9338-BA) binds with an ED50 of 150 ng/ml.
Figure 5. Recombinant Human CTRP4/C1qTNF4 Induces Neurite Outgrowth in E16-E18 Rat Cortical Neurons. A) Untreated E16-E18 rat cortical neurons. B) Treatment of E16-E18 rat cortical neurons treated with 2.5 µg/ml of Recombinant Human CTRP4/C1qTNF4 (Catalog # 8357-TN) results in neurite outgrowth.
Figure 6. Recombinant Human CTRP9/C1qTNF9 Stimulates CXCL10 Secretion by RAW 264.7 Mouse Monocyte/Macrophage Cells. Recombinant Human CTRP9/C1qTNF9 (Catalog # 6537-TN) induces CXCL10 secretion in RAW 264.7 mouse monocyte/macrophage cells with an ED50 = 1.5 – 7.5 µg/ml.